143 related articles for article (PubMed ID: 24834290)
1. Random effect model for identifying related factors to virological response in HCV patients.
Zayeri F; Chaibakhsh S; Pourhoseingholi A; Baghban AA; Alavian SM
Gastroenterol Hepatol Bed Bench; 2013; 6(Suppl 1):S65-9. PubMed ID: 24834290
[TBL] [Abstract][Full Text] [Related]
2. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
[TBL] [Abstract][Full Text] [Related]
4. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
5. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological interventions for acute hepatitis C infection.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
[TBL] [Abstract][Full Text] [Related]
7. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML; Chuang WL
J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
[TBL] [Abstract][Full Text] [Related]
9. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
10. Aminoadamantanes for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
[TBL] [Abstract][Full Text] [Related]
11. Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.
Araújo AR; Peruhype-Magalhães V; Coelho-dos-Reis JG; Chaves LP; de Lima TA; Pimentel JP; de Paula L; de Almeida CM; Tarragô AM; Tateno A; Levi JE; Teixeira-Carvalho A; Martins-Filho OA; Lira Eda F; Torres KL; Talhari S; Malheiro A
Immunol Lett; 2013; 154(1-2):61-9. PubMed ID: 23973662
[TBL] [Abstract][Full Text] [Related]
12. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
14. Management issues in chronic viral hepatitis: hepatitis C.
Sievert W
J Gastroenterol Hepatol; 2002 Apr; 17(4):415-22. PubMed ID: 11982722
[TBL] [Abstract][Full Text] [Related]
15. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
16. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Rivero-Juárez A; Mira JA; Pérez-Camacho I; Macías J; Camacho A; Neukam K; Torre-Cisneros J; Merchante N; Pineda JA; Rivero A;
J Antimicrob Chemother; 2011 Jun; 66(6):1351-3. PubMed ID: 21415037
[TBL] [Abstract][Full Text] [Related]
17. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
Ullah S; Rehman HU; Idrees M
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
Hsu CS; Liu CH; Liu CJ; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2009; 14(1):45-54. PubMed ID: 19320236
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
